444325-44-4

Upstream product

• 63133-82-4 2-chloro-4,6-dimethylaniline 
• 444325-43-3 2-chloro-N-(2-chloro-4,6-dimethyl-phenyl)-acetamide 

Downstream Products

• 444325-48-8 7-(2-chloro-4,6-dimethyl-phenyl)-2-ethyl-6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid ethyl ester 
• 444325-46-6 1-(2-chloro-4,6-dimethyl-phenyl)-imidazolidin-2-ylideneamine 
• 444325-45-5 N¹-(2-chloro-4,6-dimethyl-phenyl)-ethane-1,2-diamine 

Relevant academic research and scientific papers

Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists

7-Aryl-6,7-dihydroimidazoimidazoles represent a novel series of high-affinity corticotropin-releasing factor 1 receptor antagonists. Here, we report their synthesis and SAR as well as behavioral activity of two exemplary compounds, 7b and 7k, in a mouse canopy model of anxiety.

Imidazolyl derivatives as corticotropin releasing factor inhibitors

The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.